A randomised trial of dolutegravir (DTG)-based antiretroviral therapy vs standard of care (SOC) in children with HIV infection starting first-line or switching to second-line ART
Phase of Trial: Phase II/III
Latest Information Update: 14 Nov 2017
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms ODYSSEY
- Sponsors ViiV Healthcare
- 07 Nov 2017 Status changed from not yet recruiting to recruiting.
- 10 Jun 2017 Biomarkers information updated
- 26 Jan 2016 Planned initiation date changed from 30 Jun 2015 to 1 May 2016, according to ClinicalTrials.gov record.